Hostname: page-component-5c6d5d7d68-lvtdw Total loading time: 0 Render date: 2024-08-09T11:42:14.901Z Has data issue: false hasContentIssue false
  • English
  • Français

The role of the ‘central’ cholecystokinin-B receptor in panic disorder

Published online by Cambridge University Press:  18 September 2015

H.J.G.M. Van Megen ,
H.G.M. Westenberg  and
J.A. Den Boer
H.J.G.M. Van Megen*
Affiliation:
Rudolf Magnus Institute of Neurosciences
H.G.M. Westenberg
Affiliation:
Rudolf Magnus Institute of Neurosciences
J.A. Den Boer
Affiliation:
Afdeling Biologische Psychiatrie, Academisch ziekenhuis Groningen, 9700 RB Groningen
*
Rudolf Magnus Institute of Neurosciences, Dept. of Psychiatry, University Hospital Utrecht, P.O. Box 85500, 3508 GA Utrecht
Get access Rights & Permissions [Opens in a new window]

Summary

Research investigating the neurobiological underpinnings of anxiety disorder have mainly been focused on dysfunction of the GABA, noradrenergic and serotonergic (5-HT) neuronal systems. Just recently, in both animal and human studies, evidence has been found for a possible role of the cholecystokinin (CCK) neuronal system in the pathogenesis of anxiety disorder.

Behaviorally, animal studies revealed anxiogenic-like properties for the ‘central’ CCKB receptor agonists, while CCKB receptor antagonists displayed intrinsic anxiolytic properties. Similarly, in man, CCKB receptor agonists, like pentagastrin and CCK4, were found to be able to elicited panic attacks in both panic disorder (PD) patients and healthy volunteers. These effects appear due to stimulation of the CCKB receptor. In addition, clinically effective panicolytic agents reduce the sensitivity to CCK4 in PD patients. Taken together, these findings may suggest a role for CCK in the neurobiology of PD. On the other hand, there is circumstantial evidence for involvement of several other neuronal systems, such as the serotonergic, noradrenergic and GABA-ergic system, in the regulation of anxiety. Interestingly, evidence has been found for an interaction between CCK and 5-HT and that this interaction plays a role in the mediation of anxiety.

This presentation will critically discuss the evidence for the role of the CCKB receptor in anxiety and in addition, will focus on the putative evidence that the role of CCK in anxiety is mediated by its interaction with the serotonergic neuronal system.

Keywords

NeuropeptidescholecystokininCCK-B-receptoranxiety disordersNeuropeptidecholecystokinineCCK-B-receptor5-HTangststoornis
Type
Research Article
Information
Acta Neuropsychiatrica , Volume 8 , Issue 4 , December 1996 , pp. 99 - 101
Copyright
Copyright © Scandinavian College of Neuropsychopharmacology 1996

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Literatuur

1.Bradwejn, J, Koszycki, D, Shriqui, C. Enhanced sensitivity to cholecystokinin tetrapeptide in panic disorder. Arch Gen Psychiat 1991; 48: 603–10.CrossRefGoogle ScholarPubMed
2.Van Megen, HJGM, Den Boer, JA, Westenberg, HGM. Pentagastrin induced panic attacks: enhanced sensitivity in panic disorder patients. Psychopharmacology 1994; 114: 449–55.Google Scholar
3.Van Megen, HJGM, Den Boer, JA, Westenberg, HGM. Single blind dose response study with cholecystokinin (CCK-4) in panic disorder patients. Eur neuropsychopharm 1996; 6:187–94.CrossRefGoogle Scholar
4.Bradwejn, J, Koszycki, D, Couetoux du tertre, A, Van Megen, HJGM, Westenberg, HGM, Den Boer, JA, Karkanias, C, Haigh, J. The panicogenic effects of cholecystokinin tetrapeptide are antagonized by L-365,260, a central cholecystokinin receptor antagonist in patients with panic disorder. Arch Gen Psychiat 1994;51:486–93.CrossRefGoogle ScholarPubMed
5.Van Megen, HJGM, Westenberg, HGM, Den Boer, JA. Effect of the selective serotonin reuptake inhibitor (SRRI) Fluvoxamine on CCK-4 induced panic attacks. Psychopharmacology 1996; in press.Google Scholar
6.Kramer, MS, Cutler, NR, Ballenger, JC, Patterson, WM, Mendels, J, Chenault, A, Shrivastava, R, Matzura-Wolfe, D, Lines, C, Reines, S. A placebo controlled trial of L-365,260, a CCKB antagonist, in panic disorder. Biol Psychiat 1995; 37:462–6.Google Scholar
7.Van Megen, HJGM, Westenberg, HGM, Den Boer, JA. Effect of the cholecystokinin-B (CCK-B) receptor antagonist L-365,260 on lactate induced panic attacks (PA). Biol Psychiat 1996; 40:804–6.CrossRefGoogle Scholar
8.Bradwejn, J and Koszycki, D. Imipramine antagonism of the panicogenic effects of cholecystokinin tetrapeptide in panic disorder patients. Am J Psychiat 1995; 151: 261–3.Google Scholar
9.Paudice, P and Raiteri, M. Cholecystokinin release mediated by 5-HT3 receptors in rat cerebral cortex and nucleus accumbens. Br J Pharmacol 1991; 103: 1790–4.CrossRefGoogle ScholarPubMed
10.Raiteri, M, Paudice, P, Vallebuona, F. Inhibition by 5-HT3 receptor antagonists of release of cholecystokinin-like immunoreac-tivity from the frontal cortex of freely moving rats. Naunyn-Smiedeberg's Arch Pharmacol 1993; 347: 111–4.Google Scholar
11.Rex, A, Fink, H, Marsden, CA. Effects of BOC-CCK-4 and L-365,260 on cortical 5-HT release in Guinea pigs on exposure to the elevated plus maze. Neuropharmacology 1994; 33: 559–65.Google Scholar
12.Bickerdike, MJ, Marsden, CA, Dourish, CT, Fletcher, A. CCK antagonist effects in the rat elevated zero-maze model of anxiety: influence of 5-HT re-uptake blockade. Eur J Pharmacol 1994;271:403–11.Google Scholar